NVDIAG.
LabCom
NVDIAG—short for Nano-antibody generation using extracellular Vesicles for DIAgnostic purposes—is a collaborative laboratory (LabCom) formed through a bilateral partnership between the Laboratoire d’Ingénierie des Systèmes Macromoléculaires (LISM) and BioCytex, both located in Marseille. NVDIAG plays a leading role in advancing innovation in hemato-oncology, focusing on the development of camelid monoclonal antibodies (nano-antibodies) that serve a variety of tests and companion diagnostics solutions. This work received support from the french government under the France 2030 investment plan, as part of the Initiative d’Excellence d’Aix-Marseille Université – AMIDEX.
Client
Services
Date
Assignments
We support NVDIAG as a strategic consultant and scientific communication advisor. Our mission involves structuring the valuation project for the EV-nAb platform—an innovative technology combining extracellular vesicle engineering and nanobody selection. We also coordinate with key players in the regional innovation ecosystem and manage project stakeholders to accelerate the transition from academic research to industrial application.
We created the brand identity for NVDIAG, symbolizing the strategic alliance between academic research and industrial expertise. The visual language highlights their breakthrough 'nanobody' technology, positioning the lab as a leader in high-precision diagnostics. By developing their official website, we established a modern digital presence focused on their impact on the future of personalized medicine.
We developed a high-performance WordPress platform specifically engineered to translate NVDIAG’s complex scientific innovations into a clear and accessible digital experience. Our team manages the entire technical lifecycle, providing secure hosting and proactive maintenance to guarantee a reliable, long-term presence for this public-private partnership. This scalable infrastructure serves as the essential hub for showcasing the laboratory's ongoing breakthroughs in the field of high-precision companion diagnostics.
We manage NVDIAG’s LinkedIn presence to amplify their scientific leadership and engage the global biotechnology community. Our team curates high-impact content that highlights their breakthroughs in high-precision diagnostics and the strength of their public-private collaboration. This active social media animation ensures sustained visibility among key stakeholders, industry partners, and investors within the innovation ecosystem.
Discovering the CD19 project with Ilona TESTA! Student at NVDIAG.
Strategic potential of the CD38 target and anti-CD38 nano-antibodies developed by NVDIAG
A science-to-public publication authored by our agency
In the current biotechnology development landscape, the CD38 target and anti-CD38 antibodies represent a major scientific, industrial and economic opportunity. The NVDIAG Labcom, born from a collaboration between CNRS/Aix-Marseille Université (LISM) and BioCytex (Stago Group), is developing nanobodies (VHH) targeting CD38, designed to improve the in vitro diagnosis of haematological diseases, particularly multiple myeloma. This initiative illustrates the French model of public-private valorisation and meets the expectations of technology transfer and valorisation stakeholders, as well as venture capital investors specialised in biotechnologies.
A bespoke graphic charter
Have a project in mind?
working together
Send a message.